Medworxx
Solutions Inc. ("Medworxx") (TSX VENTURE: MWX)
today is pleased to issue the 2015 first quarter market update for the
Medworxx Patient Throughput Review (“PTR”) program. Since its
introduction in 2013, forty-eight PTRs have been delivered in five
countries: Australia, Canada, France, the United Kingdom and the United
States. International deployment continues with five PTRs scheduled for
delivery in four counties during the first quarter ending March 31,
2015; one in Australia, one in France, two in the United Kingdom, and
one in the United States. Medworxx and its consulting partners work with
each site to analyze PTR data to support strategic decision making and
improve patient flow performance and quality outcomes.
“Along with being a great vehicle to showcase our solution for
operational use, the PTR is becoming a great vehicle to introduce
Medworxx into new geographies as we continue to expand internationally.
Delivering five PTRs in four distinct countries is evidence of this. We
are particularly excited about the reception the PTR is having within
the United States,” said Dan Matlow, President and CEO, Medworxx.
Management consulting companies, Medworxx clinical consultants and
hospital process improvement groups are able to use the Medworxx
Clinical Criteria Module to rapidly identify patient flow data,
providing visibility into patient flow issues in the hospitals that they
provide services to. Consulting companies and hospital process
improvement groups are able to license the Medworxx software to deliver
PTRs.
Medworxx also wishes to announce, that it has retained Apex Capital Inc.
(“APEX”) to provide Investor Relations, Corporate Marketing,
Communication Enhancement and Strategic Awareness services. The contract
is for an initial period of four months and may be extended by mutual
consent. Under the terms of the contract, but subject to approval of the
TSX Venture Exchange, Medworxx will pay APEX $2,500 per month, reimburse
APEX for certain pre-approved expenses, and grant APEX options to
purchase 180,000 common shares of Medworxx at an exercise price of
$0.455 per share vesting in stages over a period of twelve months from
the date of grant with one quarter of such options vesting immediately
and every three months thereafter. Katrin Tosine, Director of Capital
Markets at APEX will head Investor Communication and contact with the
financial community and shareholders, alongside management for the
purpose of increasing awareness of the Company and its activities.
About Apex Capital Inc.
APEX is a Merchant Capital firm which provides Investment Banking,
Investor Relations, and Public Relations consulting services to both
publicly listed and private companies. Founded in 2010 and headquartered
in Toronto, APEX is led by Brett Allan, CEO and Katrin Tosine, Director
of Capital Markets. APEX builds customized financial consulting and
marketing programs for clients to drive results in the Financial
Community specifically for micro, small and mid-cap companies.
Industries of influence include; technology, mining, oil & gas and life
sciences.
About Medworxx
Medworxx delivers health information technology solutions to over 350
hospitals internationally. Medworxx helps hospitals meet patient flow
challenges, and requirements in compliance and education. Medworxx
Clinical Criteria – flagship of Medworxx Patient Flow that includes
electronic bed board and independent assessment components – currently
serves 34% of the acute care beds in Canada. Founded in 2004, Medworxx
is based in Toronto, ON, and publicly traded on the TSX Venture
Exchange: MWX.
For more information visit: http://www.medworxx.com.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements. Often, but
not always, forward-looking statements can be identified by the use of
words such as “plans”, “expects” or “does not expect”, “is expected”,
“estimates”, “intends”, “anticipates” or “does not anticipate”, or
“believes”, or “recurring” or variations of such words and phrases or
state that certain actions, events or results “may”, “could”, “would”,
“might” or “will” be taken, occur or be achieved. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors, such as competition, technological changes, the changing needs
of hospitals, the financial condition of Medworxx’s current and
potential customers, foreign currency exchange rates, as well as general
economic conditions, which may cause the actual results, performance or
achievements of Medworxx to be materially different from any future
results, performance or achievements expressed or implied by the
forward-looking statements. Actual results and developments are likely
to differ, and may differ materially, from those expressed or implied by
the forward-looking statements contained in this press release. There
can be no assurance that forward-looking statements will prove to be
accurate, as actual results and future events could differ materially
from those anticipated in such statements. Accordingly, readers should
not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this released.
www.medworxx.com
Copyright Business Wire 2015